Phase I trial of a sustained-exposure formulation of gacyclidine (OTO-311) as a potential therapy for tinnitus.
Phase of Trial: Phase I
Latest Information Update: 02 Mar 2017
At a glance
- Drugs Gacyclidine (Primary)
- Indications Tinnitus
- Focus Adverse reactions
- Sponsors Otonomy
- 02 Mar 2017 According to an Otonomy media release, status changed from recruiting to completed.
- 03 Nov 2016 According to an Otonomy media release, several dose cohorts in the trial have been completed without patient tolerability concerns and the trial will remain open into 2017 pending the potential evaluation of additional dose levels in order to establish a maximum tolerated dose.
- 16 Nov 2015 This trial is expected to be completed in the first half of 2016, according to an Otonomy media release.